What was studied?
The study randomized 50 adults receiving HIV therapy who had abdominal fat accumulation. It compared tesamorelin with placebo over six months.
What did the researchers report?
Visceral fat decreased and liver fat showed a modest reduction with tesamorelin relative to placebo. Early fasting-glucose changes were also observed, underlining the value of safety monitoring.
What are the limits?
The authors described the study as preliminary. Its size, duration and HIV-specific population limit broader conclusions, and changes in imaging measurements do not alone establish long-term health benefits.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.